US2009111178A1PendingUtilityA1

Gene reporter assay, kit, and cells for determining the presence and/or the level of a molecule that activates signal transduction activity of a cell surface protein

Assignee: LE CT NATIONALE DE LA RECH SCIPriority: Oct 4, 2002Filed: Jun 19, 2007Published: Apr 30, 2009
Est. expiryOct 4, 2022(expired)· nominal 20-yr term from priority
G01N 33/5005
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a commercializable cell and to a gene reporter assay method and a kit which use this cell to determine the presence and/or the level of a molecule that activates signal transduction activity of a cell surface protein. This cell is treated in such a manner that it will have a sufficiently long shelf life for its intended purpose, whereupon at the end of its useful shelf life or at the end of its use, i.e., in an assay, the cell undergoes cellular death.

Claims

exact text as granted — not AI-modified
1 . A method for commercializing a cell line having a desired biological activity, comprising:
 treating the cell line such that the cell line will maintain the desired biological activity for no more than about 30 days at a temperature above freezing, but cannot be propagated or maintained thereafter;   freezing the treated cell line at a temperature and under conditions such that it will resume the required biological activity after thawing; and   selling or distributing the frozen treated cell line whereby said cells will be available for a limited time but cannot be propagated and maintained indefinitely for multiple uses.   
     
     
         2 . A method in accordance with  claim 1 , wherein said treating step comprises treating the cell line such that the cell line will maintain the desired biological activity for at least about 8 hours, but no more than about 30 days at a temperature above freezing. 
     
     
         3 . A method in accordance with  claim 2 , further comprising the step of suspending the treated cell line in a solution containing a cryopreservative before said freezing step. 
     
     
         4 . A method in accordance with  claim 3 , wherein the cryopreservative is a combination of DMSO and glycerol and the solution contains 2.5% DMSO and 10% glycerol. 
     
     
         5 . A method in accordance with  claim 3 , wherein the solution comprises RPMI medium and 40% fetal bovine serum. 
     
     
         6 . A method in accordance with  claim 2 , wherein said treating step treats the cell line with an agent, which is anti-mitotic and pro-apoptotic, in a sufficient amount and for a sufficient time such that the cell line will maintain the desired biological activity for at least about 8 hours, but will lose said signal transduction activity and undergo cellular death in no more than about 30 days at a temperature above freezing. 
     
     
         7 . A method in accordance with  claim 6 , wherein the anti-mitotic and pro-apoptotic agent is vinblastine. 
     
     
         8 . A method in accordance with  claim 6 , wherein the anti-mitotic and pro-apoptotic agent is 5-fluorouracil. 
     
     
         9 . A method in accordance with  claim 1 , wherein, in said freezing step, the temperature is about −80° C.

Join the waitlist — get patent alerts

Track US2009111178A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.